Skip to main content
CAPR
NASDAQ Life Sciences

Capricor Q2 Loss Widens to $40.7M; Cash Drops to $237.9M Amid FDA Review Uncertainty

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$4.82
Mkt Cap
$243.809M
52W Low
$2.96
52W High
$40.37
52W Position info
63% above low
Off High info
88% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

CAPR sits 63% above its 52-week low of $2.96.

Summary

Capricor reported a wider Q2 loss of $40.7M and a cash decline to $237.9M, while withdrawing its injunction against NS Pharma and disclosing an FDA Form 483 observation, all ahead of the August 22 PDUFA decision.


Key Events · Earnings and Guidance · CAPR

  • Q2 Loss Widens 57%

    Net loss of $40.7 million ($0.70/share) versus $25.9 million ($0.57/share) in Q2 2025, driven by a 55% increase in operating expenses to $42.9 million.

  • Cash Burn Accelerates

    Cash, equivalents, and marketable securities fell to $237.9 million from $318.1 million at year-end 2025, a decline of $80.2 million in six months.

  • NS Pharma Injunction Withdrawn

    Capricor withdrew its motion for preliminary injunction against NS Pharma, moving the contractual dispute to arbitration expected to begin this fall.

  • FDA Form 483 Observation

    An FDA Bioresearch Monitoring inspection in July 2026 resulted in one Form 483 observation; the company has submitted responses and awaits feedback.


Analysis · CAPR · Life Sciences

Capricor's second-quarter results show a sharply widening loss and accelerating cash burn as the company prepares for a potential FDA decision on Deramiocel. The net loss of $40.7 million is 57% higher than the same quarter last year, driven by a 55% jump in operating expenses. Cash fell by $80 million in six months to $237.9 million, though management says this is enough for at least twelve months. The filing also reveals the company withdrew its preliminary injunction motion against NS Pharma, moving that dispute to arbitration, and disclosed a Form 483 observation from an FDA manufacturing inspection. These updates come just nine days before the August 22 PDUFA date, following a negative advisory committee vote and a securities fraud lawsuit.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CAPR was trading at $4.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $243.8M. The 52-week trading range was $2.96 to $40.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CAPR - Latest Insights

CAPR
Nov 10, 2026, 5:25 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.35
Real-time Price: $9.32 info
Change: -$0.030 (-0.32%) info
Market Cap: $554.094M info
CAPR
Nov 10, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $9.10
Real-time Price: $9.32 info
Change: +$0.220 (+2%) info
Market Cap: $554.094M info
CAPR
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.91
Real-time Price: $9.32 info
Change: +$0.415 (+5%) info
Market Cap: $554.094M info
CAPR
Nov 09, 2026, 9:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.08
Real-time Price: $9.32 info
Change: +$0.237 (+3%) info
Market Cap: $554.094M info
CAPR
Oct 05, 2026, 12:12 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $8.22
Real-time Price: $9.32 info
Change: +$1.10 (+13%) info
Market Cap: $554.094M info